Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Eiger Biopharma (NQ: EIGR )

11.02 USD -0.84 (-7.08%)
Official Closing Price Updated: 6:03 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Eiger Biopharma

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress
Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced additional positive lonafarnib (LNF) data from the LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program presented at The... 
From PR Newswire
The Week Ahead In Biotech: PDUFA Dates, IPOs And More
Here's a few must-watch biotech catalysts this week. Conferences Panamerican League of Associations for Rheumatology Congress ... 
Tags Previews NVS Biotech
From Benzinga
Eiger BioPharmaceuticals to Participate in Conferences in April
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that Eiger will participate at upcoming... 
From PR Newswire
Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, today announced the first patient dosed in PREVENT, a Phase 2,... 
From PR Newswire
BRIEF-Eiger Biopharmaceuticals Sees Phase 3 D-Livr Trial Starting In Second Half 2018?
* EIGER BIOPHARMACEUTICALS ANNOUNCES POSITIVE GUIDANCE FOLLOWING FDA MEETING ON HEPATITIS DELTA VIRUS REGISTRATION PROGRAM 
Tags companyNews
From Reuters: Company News
Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program
- Phase 3 D-LIVR Trial Planned to Initiate in Second Half 2018 
From PR Newswire
46 Biggest Movers From Yesterday
Gainers BlueLinx Holdings Inc. (NYSE: BXC) shares gained 77.52 percent to close at $28.03 after the company reported a $413 ... 
Tags MARA PICO OGEN
From Benzinga
32 Stocks Moving In Monday's Mid-Day Session
Gainers Arcadia Biosciences Inc (NASDAQ: RKDA) shares jumped 80.3 percent to $18.80. BlueLinx Holdings Inc. (NYSE: ... 
Tags MACK Losers CGNT
From Benzinga
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
- Hepatitis Delta Virus Program Moving into Phase 3 in 2018 
From PR Newswire
Eiger BioPharmaceuticals to Participate in U.S. and International Investor and Partnership Conferences in March
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger,... 
From PR Newswire
Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress™ Meeting
Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that abstracts from its LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program will be presented at The International Liver... 
From PR Newswire
Eiger BioPharmaceuticals to Participate in Two Upcoming Investor Conferences in February
Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger,... 
From PR Newswire
Sum Up The Parts: IWC Could Be Worth $113
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
42 Biggest Movers From Yesterday
Gainers Spi Energy Co Ltd (ADR) (NASDAQ: SPI) climbed 63.75 percent to close at $1.04 on Tuesday after announcing ... 
Tags SRNE RIOT NEWA
From Benzinga
Eiger BioPharmaceuticals reports disappointing study results
Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR) reported disappointing results from a Phase 2 LIBERTY study in pulmonary arterial hypertension sending the stock price crashing $7.90 to close at $8.10.... 
From MarketMinute.com Stock News
Eiger BioPharmaceuticals is Now Oversold (EIGR)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a... 
Tags Stocks
From Market News Video
Mid-Afternoon Market Update: U.S. Stocks Turn Negative; Energizer Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 0.11 percent to 25,774.28 while the NASDAQ declined 0.48 percent to 7,226.49. The ... 
Tags ENR Eurozone Intraday Update
From Benzinga
40 Stocks Moving In Tuesday's Mid-Day Session
Gainers Spi Energy Co Ltd (ADR) (NASDAQ: SPI) jumped 57.5 percent to $1.00 after announcing establishment of Blockchain-based ... 
Tags RXII NNDM ITUS
From Benzinga
Mid-Day Market Update: Blackhawk Surges On News Of Acquisition By Silver Lake; Eiger Biopharmaceuticals Shares Slide
Midway through trading Tuesday, the Dow traded up 0.66 percent to 25,972.30 while the NASDAQ climbed 0.57 percent to 7,302.76. The ... 
Tags IO Mid/Day Market Update LPL
From Benzinga
Mid-Morning Market Update: Markets Open Higher; Citigroup Profit Tops Expectations
Following the market opening Tuesday, the Dow traded up 1.02 percent to 26,066.25 while the NASDAQ climbed 0.89 percent to 7,325.93. The ... 
Tags EIGR HAWK Mid/Morning Market Update
From Benzinga
Markets soar on upbeat earnings
Upbeat earnings sent the markets soaring to a sharply higher open with the Dow jumping 184 points to 25,987. Nasdaq gained 46 points to 7307. 
Tags Market News
From MarketMinute.com Market Updates
Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint
- End of Phase 2 Meeting Scheduled for HDV in February 2018 
From PR Newswire
3 Pharma and Biotech Stocks to Watch Out for in 2018
2017 turned out to be a pretty good year for pharma and biotech stocks with the Nasdaq Biotechnology index and the NYSE Arca Pharmaceutical index gaining 18.7% and 11.8%, respectively. 
Tags Stocks / Equities Healthcare Pharma/Biotech
From Blogs - TalkMarkets
Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Eldon Mayer to its Board of Directors.... 
From PR Newswire
Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients
- ULTRA Study Data Expected in Second Half 2018 
From PR Newswire
Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of David Apelian, MD, PhD, MBA as Chief... 
From PR Newswire
Eiger BioPharmaceuticals to Present at Biotech Showcase™ 2018
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory, President and CEO, will... 
From PR Newswire
BRIEF-Eiger Biopharma Files For Mixed Shelf Of Up To $125 Mln
* EIGER BIOPHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $125 MILLION - SEC FILING Source text: (http://bit.ly/2nUkpvR) Further company coverage: 
Tags companyNews
From Reuters: Company News
Eiger BioPharmaceuticals to Present at Jefferies 2017 Healthcare Conference
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory, President and CEO of Eiger,... 
From PR Newswire
Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results
-Clinical Results Planned in Each of Four Orphan Disease Programs by 4Q 2018 
From PR Newswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.